<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Activating mutations of NRAS are common in <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo>, <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo>, and <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Like <z:hpo ids='HP_0000001'>all</z:hpo> <z:mp ids='MP_0011356'>RAS</z:mp> proteins, NRAS must undergo a series of post-translational modifications for differential targeting to distinct membrane subdomains </plain></SENT>
<SENT sid="2" pm="."><plain>Although farnesylation is the obligatory first step in post-translational modifications of <z:mp ids='MP_0011356'>RAS</z:mp>, to date, successes of therapies targeting <z:chebi fb="0" ids="24017">farnesyl</z:chebi> protein transferase are modest </plain></SENT>
<SENT sid="3" pm="."><plain>Other <z:mp ids='MP_0011356'>RAS</z:mp> modifications, such as palmitoylation, are required for optimal plasma membrane association of <z:mp ids='MP_0011356'>RAS</z:mp> proteins </plain></SENT>
<SENT sid="4" pm="."><plain>However, the relative importance of these latter modifications of <z:mp ids='MP_0011356'>RAS</z:mp> in <z:e sem="disease" ids="C0598766" disease_type="Neoplastic Process" abbrv="">leukemogenesis</z:e> is not clear </plain></SENT>
<SENT sid="5" pm="."><plain>We have previously shown that expression of oncogenic NRAS using a bone marrow transduction and transplantation model efficiently induces a <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo>- or <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo>-like disease in mice </plain></SENT>
<SENT sid="6" pm="."><plain>Here we examined the role of palmitoylation in NRAS <z:e sem="disease" ids="C0598766" disease_type="Neoplastic Process" abbrv="">leukemogenesis</z:e> using this model </plain></SENT>
<SENT sid="7" pm="."><plain>We found that palmitoylation is essential for <z:e sem="disease" ids="C0598766" disease_type="Neoplastic Process" abbrv="">leukemogenesis</z:e> by oncogenic NRAS </plain></SENT>
<SENT sid="8" pm="."><plain>We also found that farnesylation is essential for NRAS <z:e sem="disease" ids="C0598766" disease_type="Neoplastic Process" abbrv="">leukemogenesis</z:e>, yet through a different mechanism from that of palmitoylation deficiency </plain></SENT>
<SENT sid="9" pm="."><plain>This study demonstrates, for the first time, that palmitoylation is an essential process for NRAS <z:e sem="disease" ids="C0598766" disease_type="Neoplastic Process" abbrv="">leukemogenesis</z:e> and suggests that the development of therapies targeting <z:mp ids='MP_0011356'>RAS</z:mp> palmitoylation may be effective in treating oncogenic NRAS-associated <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
</text></document>